Abstract
• we firstly developed a new “carrier free” core-shell metal-drug nanoparticles (HA@FeZOL). • HA@FeZOL was synthesized by coordination‐driven self‐assembly using drugs as bridging ligands. • HA@FeZOL combined radiotherapy sensitization and osteolysis inhibition to enhance the treatment of osteosarcoma. • The nanoparticles with inbuilt ZOL could escape skeleton absorption and minimize side effects. Osteosarcoma is the most common primary malignant bone tumor with the pathological essence of osteolysis, which seriously reduces the quality of life. To improve the treatment of osteosarcoma, current strategies focus on inhibiting osteolysis and cancer cell growth through combination therapy. Here, we firstly developed a new “carrier free” core-shell metal-drug nanoparticles to enhance the treatment of orthotopic osteosarcoma through inhibiting osteoclast activity and sensitizing radiotherapy. The core was formed by self-assembly of ferric ions with zoledronate (ZOL). The resultant nanoparticles with active pharmaceutical ingredient (API) content over 60 wt% and changeless ingredients of Fe and ZOL can induce efficient cell death and easy for large-scale synthesis. In addition, the inbuilt ZOL and surface modified hyaluronic acid could make the nanoparticles escape skeleton absorption and increase the concentration of zoledronate at the tumor site. Once accumulated in tumor, the released ZOL attenuated osteoclast activity around the tumors to prevent osteolysis. Meanwhile, the free radicals generated efficiently from HA@FeZOL through Fenton-like reaction sensitized radiotherapy to kill the tumor cells. The results corroborated the feasibility of HA@FeZOL mediated synergistic therapy against orthotopic osteosarcoma through sensitized radiotherapy and osteolysis inhibition. Therefore, this facile nanoplatform provides a new combinatorial strategy for treating osteosarcoma and opens a window for the application of metal-drug nanoparticles.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
